复发性缺血性阴茎异常勃起、镰状细胞病患者阴茎异常勃起及非缺血性阴茎异常勃起的诊断与管理:AUA/SMSNA指南
该指南由AUA/SMSNA制定,聚焦复发性缺血性阴茎异常勃起、镰状细胞病患者阴茎异常勃起及非缺血性阴茎异常勃起的诊断与治疗(含手术与非手术),并涵盖海绵体内血管活性药物后持续勃起的处理。文献检索纳入203篇独特文章形成推荐框架。指南强调所有阴茎异常勃起患者均应急诊评估以识别亚型,急性缺血性事件应在有指征时早期干预;非缺血性阴茎异常勃起不是急症;复发性缺血性阴茎异常勃起需处理急性发作并注重未来预防;镰状细胞病患者急性缺血性发作应首先关注泌尿外科缓解勃起,同时考虑标准镰状细胞评估与干预;医源性持续勃起的治疗方案必须与真性阴茎异常勃起的方案区分。
要点
- 所有阴茎异常勃起患者均应急诊评估,以识别亚型(急性缺血性 vs 非缺血性),急性缺血性事件应在有指征时早期干预。
- 非缺血性阴茎异常勃起不是急症,治疗必须基于患者目标、可用资源与临床经验。
- 复发性缺血性阴茎异常勃起的治疗包括处理急性发作和注重未来预防急性缺血性事件。
- 镰状细胞病患者急性缺血性阴茎异常勃起应首先关注泌尿外科缓解勃起,标准镰状细胞评估与干预应同时考虑。
- 海绵体内血管活性药物后持续勃起的治疗方案必须与真性阴茎异常勃起的方案区分。
适用人群与场景
- 阴茎异常勃起患者,包括急性缺血性、非缺血性、复发性缺血性、镰状细胞病患者以及海绵体内血管活性药物后持续勃起者。
诊断标准与关键阈值
- 阴茎异常勃起定义为持续阴茎勃起,超过性刺激后数小时或与性刺激无关,导致长时间不受控制的勃起。
- 急诊评估需识别亚型:急性缺血性与非缺血性。
处置流程与药物剂量
- 所有阴茎异常勃起患者均应急诊评估以识别亚型(急性缺血性 vs 非缺血性)。
- 急性缺血性事件应在有指征时早期干预。
- 非缺血性阴茎异常勃起不是急症,治疗必须基于患者目标、可用资源与临床经验。
- 复发性缺血性阴茎异常勃起的治疗包括处理急性发作和注重未来预防急性缺血性事件。
- 镰状细胞病患者急性缺血性阴茎异常勃起应首先关注泌尿外科缓解勃起;标准镰状细胞评估与干预应同时考虑。
- 海绵体内血管活性药物后持续勃起的治疗方案必须与真性阴茎异常勃起的方案区分。
研究设计与关键结果
- 指南由AUA/SMSNA制定,通过系统文献检索(急诊照护研究所检索1960年1月1日至2020年5月1日文献;太平洋西北循证实践中心检索1946年至2021年2月19日文献),初检4117篇潜在相关文章,排除3437篇,最终纳入203篇独特文章。
- 指南提供非缺血性阴茎异常勃起、复发性缺血性阴茎异常勃起及镰状细胞病患者阴茎异常勃起的治疗(非手术与手术)临床框架,并涵盖海绵体内血管活性药物后持续勃起的治疗。
- AUA关于阴茎异常勃起诊断和急性缺血性阴茎异常勃起治疗的指南已于2021年发布。
证据类型、等级与局限
- 证据类型:指南(AUA/SMSNA)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 所有阴茎异常勃起患者均应急诊评估以识别亚型,急性缺血性事件应在有指征时早期干预。
- 非缺血性阴茎异常勃起不是急症,治疗必须基于患者目标、可用资源与临床经验。
- 复发性缺血性阴茎异常勃起需处理急性发作并注重未来预防急性缺血性事件。
- 镰状细胞病患者急性缺血性阴茎异常勃起应首先关注泌尿外科缓解勃起,标准镰状细胞评估与干预应同时考虑。
- 医源性持续勃起的治疗方案必须与真性阴茎异常勃起的方案区分。
指南或共识出处
- AUA/SMSNA指南:复发性缺血性阴茎异常勃起、镰状细胞病患者阴茎异常勃起及非缺血性阴茎异常勃起的诊断与管理(J Urol)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Priapism is a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation and results in a prolonged and uncontrolled erection. Given its time-dependent and progressive nature, priapism is a situation that both urologists and emergency medicine practitioners must be familiar with and comfortable managing.
METHODOLOGY: A comprehensive search of the literature on acute ischemic priapism and non-ischemic priapism (NIP) was performed by Emergency Care Research Institute for articles published between January 1, 1960 and May 1, 2020. A search of the literature on NIP, recurrent priapism, prolonged erection following intracavernosal vasoactive medication, and priapism in patients with sickle cell disease was conducted by Pacific Northwest Evidence-based Practice Center for articles published between 1946 and February 19, 2021. Searches identified 4117 potentially relevant articles, and 3437 of these were excluded at the title or abstract level for not meeting inclusion criteria. Full texts for the remaining 680 articles were ordered, and ultimately 203 unique articles were included in the report.
RESULTS: This Guideline provides a clinical framework for the treatment (non-surgical and surgical) of NIP, recurrent ischemic priapism, and priapism in patients with sickle cell disease. The treatment of patients with a prolonged erection following intracavernosal vasoactive medication is also included. The AUA guideline on the diagnosis of priapism and the treatment of acute ischemic priapism was published in 2021.
CONCLUSIONS: All patients with priapism should be evaluated emergently to identify the sub-type of priapism (acute ischemic versus non-ischemic) and those with an acute ischemic event should be provided early intervention when indicated. NIP is not an emergency and treatment must be based on patient objectives, available resources, and clinician experience. Management of recurrent ischemic priapism requires treatment of acute episodes and a focus on future prevention of an acute ischemic event. Sickle cell disease patients presenting with an acute ischemic priapism event should initially be managed with a focus on urologic relief of the erection; standard sickle cell assessment and interventions should be considered concurrent with urologic intervention. Treatment protocols for a prolonged, iatrogenic erection must be differentiated from protocols for true priapism.
参考来源
- Bivalacqua TJ, Allen BK, Brock GB, et al. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline. J Urol. 2022. PMID: 35536142. doi:10.1097/JU.0000000000002767
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。